Cargando…
Inhibitors of dipeptidyl peptidase‐4 as therapeutic agents for individuals with type 2 diabetes: a 25‐year journey
In the 25 years since the hypothesis was first described, therapeutic use of inhibitors of dipeptidyl peptidase‐4 (DPP‐4i) as a novel approach to the treatment of type 2 diabetes has become established widely, with several compounds now available to exemplify the class. Although the clinical profile...
Autores principales: | Carr, R. D., Solomon, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496331/ https://www.ncbi.nlm.nih.gov/pubmed/32426859 http://dx.doi.org/10.1111/dme.14325 |
Ejemplares similares
-
Candidate Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes
por: Jang, Yun-Mi, et al.
Publicado: (2011) -
New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022) -
Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes
por: Richter, Bernd, et al.
Publicado: (2008) -
Dipeptidyl peptidase‐4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?
por: Yabe, Daisuke, et al.
Publicado: (2014) -
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
por: Capuano, Annalisa, et al.
Publicado: (2013)